Qingdao Vland Biotech Co Ltd (603739) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qingdao Vland Biotech Co Ltd (603739) has a cash flow conversion efficiency ratio of 0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥24.29 Million ≈ $3.55 Million USD) by net assets (CN¥1.90 Billion ≈ $278.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Qingdao Vland Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Qingdao Vland Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 603739 total liabilities for a breakdown of total debt and financial obligations.
Qingdao Vland Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qingdao Vland Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raydium Semi-Conductor
TW:3592
|
0.055x |
|
ENCE Energía y Celulosa S.A
MC:ENC
|
0.024x |
|
Zhengzhou Coal Mining Machinery Group Company Limited
F:ZGC
|
0.090x |
|
Blue Moon Zinc Corp
V:MOON
|
-0.049x |
|
Quantum eMotion Corp.
V:QNC
|
-0.039x |
|
GULF KEYSTONE PETR.
F:GVP1
|
N/A |
|
STINGRAY GROUP INC.
F:317A
|
N/A |
|
Sariguna Primatirta PT
JK:CLEO
|
0.043x |
Annual Cash Flow Conversion Efficiency for Qingdao Vland Biotech Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Qingdao Vland Biotech Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Qingdao Vland Biotech Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.87 Billion ≈ $273.64 Million |
CN¥195.41 Million ≈ $28.59 Million |
0.104x | +24.19% |
| 2023-12-31 | CN¥1.83 Billion ≈ $267.11 Million |
CN¥153.59 Million ≈ $22.48 Million |
0.084x | +53.08% |
| 2022-12-31 | CN¥1.73 Billion ≈ $253.73 Million |
CN¥95.31 Million ≈ $13.95 Million |
0.055x | +3.50% |
| 2021-12-31 | CN¥1.69 Billion ≈ $246.65 Million |
CN¥89.51 Million ≈ $13.10 Million |
0.053x | -65.76% |
| 2020-12-31 | CN¥1.12 Billion ≈ $163.20 Million |
CN¥173.00 Million ≈ $25.31 Million |
0.155x | +145.11% |
| 2019-12-31 | CN¥1.03 Billion ≈ $151.05 Million |
CN¥65.33 Million ≈ $9.56 Million |
0.063x | -53.40% |
| 2018-12-31 | CN¥631.38 Million ≈ $92.39 Million |
CN¥85.75 Million ≈ $12.55 Million |
0.136x | -33.98% |
| 2017-12-31 | CN¥592.53 Million ≈ $86.71 Million |
CN¥121.90 Million ≈ $17.84 Million |
0.206x | -25.70% |
| 2016-12-31 | CN¥557.97 Million ≈ $81.65 Million |
CN¥154.49 Million ≈ $22.61 Million |
0.277x | +93.62% |
| 2015-12-31 | CN¥519.36 Million ≈ $76.00 Million |
CN¥74.27 Million ≈ $10.87 Million |
0.143x | +13.88% |
| 2014-12-31 | CN¥466.26 Million ≈ $68.23 Million |
CN¥58.55 Million ≈ $8.57 Million |
0.126x | -- |
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more